Incidence and risk factors for pacemaker implantation in light‐chain and transthyretin cardiac amyloidosis

The incidence and risk factors of pacemaker (PM) implantation in patients with cardiac amyloidosis (CA) are largely unexplored. We sought to characterize the trends in the incidence of permanent PM and to identify baseline predictors of future PM implantation in light‐chain (AL) and transthyretin (ATTR) CA.

[1]  G. Parati,et al.  Unmasking the prevalence of amyloid cardiomyopathy in the real world: results from Phase 2 of the AC‐TIVE study, an Italian nationwide survey , 2022, European journal of heart failure.

[2]  G. Barbati,et al.  Prognostic significance of unexplained left ventricular hypertrophy in patients undergoing carpal tunnel surgery , 2021, ESC heart failure.

[3]  O. Wazni,et al.  Electrophysiological Manifestations of Cardiac Amyloidosis , 2021, JACC. CardioOncology.

[4]  G. Parati,et al.  A national survey on prevalence of possible echocardiographic red flags of amyloid cardiomyopathy in consecutive patients undergoing routine echocardiography: study design and patients characterization-the first insight from the AC-TIVE Study. , 2021, European journal of preventive cardiology.

[5]  U. Eriksson,et al.  Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. , 2021, European heart journal.

[6]  C. Rapezzi,et al.  Transthyretin amyloid cardiomyopathy: An uncharted territory awaiting discovery , 2020, European Journal of Internal Medicine.

[7]  Michel G Khouri,et al.  Cardiac Implantable Electronic Devices: A Window Into the Evolution of Conduction Disease in Cardiac Amyloidosis. , 2020, JACC. Clinical electrophysiology.

[8]  W. Saliba,et al.  Atrial Fibrillation in Transthyretin Cardiac Amyloidosis: Predictors, Prevalence, and Efficacy of Rhythm Control Strategies. , 2020, JACC. Clinical electrophysiology.

[9]  T. Kovacsovics,et al.  Utility of Biomarkers in Cardiac Amyloidosis. , 2020, JACC. Heart failure.

[10]  J. Jiménez-Jáimez,et al.  Syncope and bifascicular block in the absence of structural heart disease , 2020, Scientific Reports.

[11]  W. Saliba,et al.  Prevalence, Incidence, and Impact on Mortality of Conduction System Disease in Transthyretin Cardiac Amyloidosis. , 2020, The American journal of cardiology.

[12]  P. Hansen,et al.  [Transthyretin amyloid cardiomyopathy]. , 2020, Ugeskrift for laeger.

[13]  Kathleen W. Zhang,et al.  Emerging Therapeutics for the Treatment of Light Chain and Transthyretin Amyloidosis , 2019, JACC. Basic to translational science.

[14]  F. Dominici,et al.  Epidemiology of Cardiac Amyloidosis-Associated Heart Failure Hospitalizations Among Fee-for-Service Medicare Beneficiaries in the United States. , 2019, Circulation. Heart failure.

[15]  R. Falk,et al.  Electrophysiologic assessment of conduction abnormalities and atrial arrhythmias associated with amyloid cardiomyopathy. , 2016, Heart rhythm.

[16]  P. Hawkins,et al.  A study of implanted cardiac rhythm recorders in advanced cardiac AL amyloidosis. , 2015, European heart journal.

[17]  Victor Mor-Avi,et al.  Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. , 2015, European heart journal cardiovascular Imaging.

[18]  C. Pedrinazzi,et al.  Prevention of Syncope Through Permanent Cardiac Pacing in Patients With Bifascicular Block and Syncope of Unexplained Origin: The PRESS Study , 2013, Circulation. Arrhythmia and electrophysiology.

[19]  J. Deckers,et al.  Right bundle branch block: prevalence, risk factors, and outcome in the general population: results from the Copenhagen City Heart Study. , 2013, European heart journal.

[20]  M. Gold,et al.  Long-term Outcomes in Individuals With Prolonged PR Interval or First-Degree Atrioventricular Block , 2010 .

[21]  L. Wilhelmsen,et al.  Bundle-branch block in middle-aged men: risk of complications and death over 28 years. The Primary Prevention Study in Göteborg, Sweden. , 2005, European heart journal.

[22]  F. Salvi,et al.  Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. , 2005, Journal of the American College of Cardiology.

[23]  R. Gray.  A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk , 1988 .